Clinical Trials Logo

Ischemic Stroke clinical trials

View clinical trials related to Ischemic Stroke.

Filter by:

NCT ID: NCT03824496 Completed - Clinical trials for Acute Ischemic Stroke

Head Pulse for Ischemic Stroke Detection

EPISODE
Start date: August 1, 2017
Phase:
Study type: Observational

Accurate diagnosis of stroke due to large vessel occlusion (LVO) is an essential step in providing acute stroke care to a community. The gold-standard for diagnosis LVO is brain imaging, which is impractical in the pre-hospital setting. A non-invasive method to detect LVO is needed. Using highly sensitive accelerometers, one can measure the "HeadPulse"- tiny forces exerted on the skull from the cardiac contraction. This study tests the hypothesis that LVO alters the HeadPulse characteristically. Analysis of these data along with the subjects vascular status (LVO vs. non-LVO as measured by CT angiography) will be used to create a model that can predict LVO status in suspect stroke subjects.

NCT ID: NCT03823274 Completed - Ischemic Stroke Clinical Trials

Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients

Start date: April 1, 2019
Phase:
Study type: Observational [Patient Registry]

This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients

NCT ID: NCT03820882 Completed - Clinical trials for Acute Ischemic Stroke

Stent Retriever for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischemic Stroke(Catfish)

Start date: March 3, 2019
Phase: N/A
Study type: Interventional

The study is a randomized, prospective, parallel-group, multicenter, open-label, non-inferiority trial. Patients are randomized 1 : 1 to either stent retriever(Catfish) or Solitaire for endovascular therapy for acute ischemic stroke. The study aims to evaluate the benefit and safety of stent retriever(Catfish) for acute ischemic stroke therapy, as compared to Solitaire FR.

NCT ID: NCT03819452 Completed - Ischemic Stroke Clinical Trials

Impact of Vitamin D on Acute Ischemic Stroke Prognosis

IVASTO
Start date: August 1, 2018
Phase:
Study type: Observational [Patient Registry]

This is a registry for all patients admitted to hospital settings with Ischemic stroke in Mansoura University Hospital. The registry will capture patients' data, investigations and vitamin D level on admission. Follow-up is taking place using MODIFIED RANKIN SCALE

NCT ID: NCT03815292 Completed - Clinical trials for Mild Cognitive Impairment

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

Start date: October 19, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is: - to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke - to evaluate safety of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke

NCT ID: NCT03815175 Completed - Clinical trials for Coronary Artery Disease

XIENCE 28 USA Study

Start date: February 25, 2019
Phase: N/A
Study type: Interventional

The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System [EECSS], XIENCE Alpine EECSS and XIENCE Sierra EECSS) of coronary drug-eluting stents.

NCT ID: NCT03814889 Completed - Stroke Clinical Trials

Passive Tactile Stimulation for Stroke Rehabilitation

PTS
Start date: May 15, 2019
Phase: N/A
Study type: Interventional

Stroke can lead to weakness and spasticity in the arm or hand. The purpose of this study is to optimize the design of gentle vibratory stimulation delivered to the hands of individuals with chronic stroke, and explore the effect on range of movement and spasticity.

NCT ID: NCT03805308 Completed - Ischemic Stroke Clinical Trials

The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke

TESLA
Start date: July 16, 2019
Phase: N/A
Study type: Interventional

The primary objective of the trial is to establish the effectiveness of IAT (versus medical management) in patients with moderate-large infarcts (NCCT ASPECTS 2-5) at baseline, with adaptive enrichment to better define the upper limit of infarct volume for treatment eligibility. Furthermore, the investigators aim to determine whether certain subgroups of patients with large baseline infarcts will have a greater treatment benefit. Finally, the investigators will assess the agreement of ASPECTS scores between site investigators, the core imaging lab, and automated software.

NCT ID: NCT03804060 Completed - Ischemic Stroke Clinical Trials

REperfusion With Cooling in CerebraL Acute IscheMia II

RECCLAIM-II
Start date: May 23, 2019
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine the feasibility and safety of achieving rapid hypothermia with the Proteus Intravascular Temperature Management (IVTM) system for patients experiencing acute ischemic stroke due to a large vessel occlusion.

NCT ID: NCT03803007 Completed - Clinical trials for Acute Ischemic Stroke

Acute Ischemic Stroke Interventional Study

ACTIMIS
Start date: March 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute ischemic stroke in addition to best emergency standard of care (including fibrinolysis by rtPA with or without added thrombectomy), with a specific focus on hemorrhage, whether clinically symptomatic (NIHSS score + 4 points or death, without other explanation), or seen (excluding other diagnoses) on 24-hour (hr) CT scan, serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs), and medically important events and other safety items including biological and immunological tolerability.